keyword
https://read.qxmd.com/read/38496406/a-randomized-proof-of-mechanism-trial-of-tnf-antagonism-for-motivational-anhedonia-and-related-corticostriatal-circuitry-in-depressed-patients-with-high-inflammation
#21
Michael Treadway, Sarah Etuk, Jessica Cooper, Shabnam Hossein, Emma Hahn, Samantha Betters, Shiyin Liu, Amanda Arulpragasam, Brittany DeVries, Nadia Irfan, Makiah Nuutinen, Evanthia Wommack, Bobbi Woolwine, Mandakh Bekhbat, Philip Kragel, Jennifer Felger, Ebrahim Haroon, Andrew Miller
Chronic, low-grade inflammation has been associated with motivational deficits in patients with major depression (MD). In turn, impaired motivation has been linked to poor quality of life across psychiatric disorders. We thus determined effects of the anti-inflammatory drug infliximab-a potent tumor necrosis factor (TNF) antagonist-on behavioral and neural measures of motivation in 42 medically stable, unmedicated MD patients with a C-reactive protein > 3mg/L. All patients underwent a double-blind, placebo-controlled, single-dose, randomized clinical trial with infliximab (5mg/kg) versus placebo...
March 5, 2024: Research Square
https://read.qxmd.com/read/38495280/advancements-in-autoimmune-hepatitis-management-perspectives-for-future-guidelines
#22
EDITORIAL
Marcos Mucenic
The first-line treatment for autoimmune hepatitis involves the use of prednisone or prednisolone either as monotherapy or in combination with azathioprine (AZA). Budesonide has shown promise in inducing a complete biochemical response (CBR) with fewer adverse effects and is considered an optional first-line treatment, particularly for patients without cirrhosis; however, it is worth noting that the design of that study favored budesonide. A recent real-life study revealed higher CBR rates with prednisone when equivalent initial doses were administered...
February 27, 2024: World Journal of Hepatology
https://read.qxmd.com/read/38494750/tocilizumab-successfully-treating-refractory-hearing-impairment-in-a-patient-with-cogan-syndrome-a-case-report-and-review-of-the-literature
#23
JOURNAL ARTICLE
Yan Chen, Jiarui Hu, Dongze Wu, Tong Wu, Jing Zhu
Cogan syndrome (CS) is a rare systemic vasculitis characterized primarily by nonsyphilitic interstitial keratitis and vestibular and auditory dysfunction. In this article, we report the case of a 31-year-old male diagnosed with CS for 1 year. He was admitted to the hospital with fever, dizziness, headache, tinnitus, and hearing loss. After being treated with glucocorticoids, cellular immunosuppressants, and infliximab therapy, his symptoms were greatly relieved except for hearing loss. Then, he attempted to use tocilizumab (TCZ) which was ultimately effective in controlling the auditory dysfunction...
March 17, 2024: Ear, Nose, & Throat Journal
https://read.qxmd.com/read/38493749/masld-is-related-to-impaired-alcohol-dehydrogenase-adh-activity-and-elevated-blood-ethanol-levels-role-of-tnf%C3%AE-and-jnk
#24
JOURNAL ARTICLE
Katharina Burger, Finn Jung, Katharina Staufer, Ruth Ladurner, Michael Trauner, Anja Baumann, Annette Brandt, Ina Bergheim
Elevated fasting ethanol levels in peripheral blood frequently found in metabolic dysfunction-associated steatohepatitis (MASLD) patients even in the absence of alcohol consumption are discussed to contribute to disease development. To test the hypothesis that besides an enhanced gastrointestinal synthesis a diminished alcohol elimination through alcohol dehydrogenase (ADH) may also be critical herein, we determined fasting ethanol levels and ADH activity in livers and blood of MASLD patients and in wild-type ± anti-TNFα antibody (infliximab) treated and TNFα-/- mice fed a MASLD-inducing diet...
March 12, 2024: Redox Biology
https://read.qxmd.com/read/38493113/predictive-biomarkers-for-anti-tnf-alpha-therapy-in-ibd-patients
#25
REVIEW
Manoj Kumar, Selvasankar Murugesan, Nazira Ibrahim, Mamoun Elawad, Souhaila Al Khodor
Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition characterized by severe gut inflammation, commonly presenting as Crohn's disease, ulcerative colitis or categorized as IBD- unclassified. While various treatments have demonstrated efficacy in adult IBD patients, the advent of anti-TNF therapies has significantly revolutionized treatment outcomes and clinical management. These therapies have played a pivotal role in achieving clinical and endoscopic remission, promoting mucosal healing, averting disease progression, and diminishing the necessity for surgery...
March 16, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38489323/potential-efficacy-of-t-and-b-lymphocyte-targeted-therapies-on-articular-involvement-of-patients-with-rheumatoid-arthritis-and-systemic-sclerosis-overlap-syndrome-results-from-a-2-centre-series-of-22-cases
#26
JOURNAL ARTICLE
Nans Lebel, Isabelle Marie, Julien Grosjean, Pauline Brevet, Mathilde Leclercq, Anaël Dumont, Hervé Levesque, Ygal Benhamou, Christian Marcelli, Thierry Lequerre, Olivier Vittecoq
OBJECTIVES: To analyse in routine practice the efficacy of targeted therapies on joint involvement of patients with rheumatoid arthritis/systemic sclerosis (RA/SSc) overlap syndrome. METHODS: This was a retrospective analysis of medical records of two academic centres over a 10-year period. Joint response to targeted therapies was measured according to EULAR criteria based on Disease Activity Score (DAS)-28. In addition, changes in CRP level and glucocorticoid consumption were recorded...
March 13, 2024: Clinical and Experimental Rheumatology
https://read.qxmd.com/read/38488984/performance-of-eight-infliximab-population-pharmacokinetic-models-in-a-cohort-of-dutch-children-with-inflammatory-bowel-disease
#27
JOURNAL ARTICLE
Nanja C Bevers, Ron J Keizer, Dennis R Wong, Arta Aliu, Marieke J Pierik, Luc J J Derijks, Patrick F van Rheenen
BACKGROUND AND OBJECTIVE: Efficacy of infliximab in children with inflammatory bowel disease can be enhanced when serum concentrations are measured and further dosing is adjusted to achieve and maintain a target concentration. Use of a population pharmacokinetic model may help to predict an individual's infliximab dose requirement. The aim of this study was to evaluate the predictive performance of available infliximab population pharmacokinetic models in an independent cohort of Dutch children with inflammatory bowel disease...
March 15, 2024: Clinical Pharmacokinetics
https://read.qxmd.com/read/38487649/efficacy-of-biologics-in-the-treatment-of-primary-sclerosing-cholangitis-associated-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis
#28
REVIEW
David Huynh, Denis Rubtsov, Myat Myat Khaing
This is the first systematic review and meta-analysis that aims to address the scarcity of research on the use of biological therapy in primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD) and the historical inadequacy of therapeutic options. Its purpose is to investigate this matter comprehensively and furnish guidance for clinical practice. Utilizing Embase, PubMed, Medline, and clinicaltrials.gov studies investigating the roles of biologics and antibiotics in PSC-IBD were identified. The systematic literature review encompassed articles published from inception through September 2023...
March 2024: Curēus
https://read.qxmd.com/read/38487360/the-neuro-ophthalmology-of-tuberculosis
#29
REVIEW
Ritu Shree, Karthik V Mahesh, Aastha Takkar, Manish Modi, Manoj K Goyal, Vivek Lal
Tuberculosis (TB) is a global health concern and central nervous system (CNS) TB leads to high mortality and morbidity. CNS TB can manifest as tubercular meningitis, tuberculoma, myelitis, and arachnoiditis. Neuro-ophthalmological involvement by TB can lead to permanent blindness, ocular nerve palsies and gaze restriction. Visual impairment is a dreaded complication of tubercular meningitis (TBM), which can result from visual pathway involvement at different levels with varying pathogenesis. Efferent pathway involvement includes cranial nerve palsies and disorders of gaze...
2024: Neuro-ophthalmology
https://read.qxmd.com/read/38486260/efficacy-and-safety-of-infliximab-in-systemic-sarcoidosis-according-to-genphenresa-organ-involvement-phenotype-a-retrospective-study-of-55-patients
#30
JOURNAL ARTICLE
Etienne Rivière, Wendy Jourde, Noémie Gensous, Xavier Demant, Emmanuel Ribeiro, Pierre Duffau, Patrick Mercié, Jean-François Viallard, Estibaliz Lazaro
BACKGROUND: Infliximab is currently recommended as a third-line treatment for refractory sarcoidosis. Data in function of clinical phenotype are currently lacking. We evaluated patients' characteristics and responses to infliximab according to their GenPhenReSa cluster. METHODS: We evaluated clinical and biological characteristics of patients diagnosed with sarcoidosis who received infliximab between September 2008 and April 2019 at our centre. RESULTS: Fifty-five patients (median disease duration, 87 months) received infliximab: 48 (87%) as a second- or third-line treatment, and 7 (13%) as a first-line treatment...
March 14, 2024: Respiratory Research
https://read.qxmd.com/read/38485454/risk-of-serious-infection-associated-with-different-classes-of-targeted-therapies-used-in-psoriatic-arthritis-a-nationwide-cohort-study-from-the-french-health-insurance-database-snds
#31
JOURNAL ARTICLE
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
OBJECTIVE: To assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings. METHODS: This nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, secukinumab, ixekizumab, ustekinumab, and tofacitinib) from 1 January 2015 to 30 June 2021...
March 14, 2024: RMD Open
https://read.qxmd.com/read/38481157/clinical-features-of-inflammatory-bowel-disease-unclassified-a-case-control-study
#32
JOURNAL ARTICLE
Yupei Shao, Yixiao Zhao, Hong Lv, Pengguang Yan, Hong Yang, Jingnan Li, Ji Li, Jiaming Qian
BACKGROUND: Approximately 10-15% of inflammatory bowel disease (IBD) patients with overlapping features of ulcerative colitis (UC) and Crohn's disease (CD) are termed as inflammatory bowel disease unclassified (IBDU). This study aimed to describe the clinical features of IBDU and evaluate the potential associated factors of reclassification. METHODS: The clinical data of 37 IBDU patients were retrospectively analyzed from November 2012 to November 2020. 74 UC and 74 CD patients were randomly selected and age- and sex-matched with the 37 IBDU patients...
March 13, 2024: BMC Gastroenterology
https://read.qxmd.com/read/38477863/comparative-maintenance-performance-of-all-biologic-agents-and-small-molecules-in-ulcerative-colitis-a-network-meta-analysis
#33
JOURNAL ARTICLE
Theodore Rokkas, Javier P Gisbert, Konstantinos Ekmektzoglou, Themistocles Dassopoulos, Yaron Niv, Colm O'Morain
BACKGROUND AND AIMS: Βiologic agents and small molecules have expanded the therapeutic armamentarium of moderate to severe ulcerative colitis (UC). However, their comparative efficacy and safety performance as maintenance treatments have not been sufficiently explored. We performed a systematic review and network meta-analysis (NWM) to assess the comparative efficacy and safety of all approved and emerging treatments for maintenance in moderate to severe UC. METHODS: We searched Pubmed/Medline, EMBASE, and Cochrane Library databases for relevant RCTs through April 2023...
March 12, 2024: European Journal of Gastroenterology & Hepatology
https://read.qxmd.com/read/38477410/combination-biologic-therapy-in-pediatric-inflammatory-bowel-disease-safety-and-efficacy-over-a-minimum-12-month-follow-up-period
#34
JOURNAL ARTICLE
Magdalena Wlazlo, Monika Meglicka, Anna Wiernicka, Marcin Osiecki, Malgorzata Matuszczyk, Jaroslaw Kierkus
OBJECTIVES: The severe course of inflammatory bowel diseases (IBDs) refractory to advanced therapies in children results in the search for new therapeutic methods. The aim of this study was to evaluate the efficacy and safety of dual therapy with biologics in a cohort of children with IBD. METHODS: Retrospective analysis of data from 29 children with a diagnosis of IBD, 19 with ulcerative colitis (66%), 10 with Crohn's disease (CD) (34%) qualified for dual biological therapy (DBT)...
March 13, 2024: Journal of Pediatric Gastroenterology and Nutrition
https://read.qxmd.com/read/38476303/refractory-hidradenitis-suppurativa-a-diagnosis-to-consider
#35
Rita Ornelas Saraiva, Christopher Saunders, Margarida Varela Dos Santos, Diana Carvalho, Rafaela Loureiro, Jaime Ramos
Hidradenitis suppurativa is a chronic inflammatory disease associated with multiple comorbidities, and its association with lymphoma has recently been a topic of debate. However, it is still controversial whether this risk can be attributed to the disease itself or whether it has any relationship with immunosuppressive treatment. Here, we describe the case of a patient with severe perianal hidradenitis suppurativa treated with methotrexate and infliximab, whose exacerbation with persistence of severe symptoms refractory to adequate treatment led to the diagnosis of diffuse large non-Hodgkin B-cell lymphoma...
February 2024: GE Portuguese Journal of Gastroenterology
https://read.qxmd.com/read/38476237/poor-prognostic-factors-of-pharmacokinetic-origin-predict-outcomes-in-inflammatory-bowel-disease-patients-treated-with-anti-tumor-necrosis-factor-%C3%AE
#36
JOURNAL ARTICLE
Elizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, Maria Chaparro, Paolo Gionchetti, Fernando Rizzello, Javier P Gisbert, Emily K Wright, Julien D Schulberg, Amy L Hamilton, Dermot P B McGovern, Thierry Dervieux
INTRODUCTION: We evaluated baseline Clearance of anti-tumor necrosis factors and human leukocyte antigen variant (HLA DQA1*05) in combination as poor prognostic factors (PPF) of pharmacokinetic (PK) origin impacting immune response (formation of antidrug antibodies) and disease control of inflammatory bowel disease (IBD) patients treated with infliximab or adalimumab. METHODS: Baseline Clearance was estimated in IBD patients before starting treatment using weight and serum albumin concentrations...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38472447/ct-based-pancreatic-radiomics-predicts-secondary-loss-of-response-to-infliximab-in-biologically-na%C3%A3-ve-patients-with-crohn-s-disease
#37
JOURNAL ARTICLE
Tian Yang, Jing Feng, Ruchen Yao, Qi Feng, Jun Shen
OBJECTIVES: Predicting secondary loss of response (SLR) to infliximab (IFX) is paramount for tailoring personalized management regimens. Concurrent pancreatic manifestations in patients with Crohn's disease (CD) may correlate with SLR to anti-tumor necrosis factor treatment. This work aimed to evaluate the potential of pancreatic radiomics to predict SLR to IFX in biologic-naive individuals with CD. METHODS: Three models were developed by logistic regression analyses to identify high-risk subgroup prone to SLR...
March 13, 2024: Insights Into Imaging
https://read.qxmd.com/read/38469431/vancomycin-and-ustekinumab-combination-therapy-in-acute-ulcerative-colitis
#38
Khue M Nguyen, Emily K Wright
The role of antibiotics in the treatment of ulcerative colitis is limited. We present a case of a 25-year-old woman who presented with a flare of ulcerative colitis after an episode of infectious gastroenteritis on a background of known primary sclerosing cholangitis. After the flare, she experienced persistent abdominal pain and diarrhea associated with elevated fecal calprotectin and deep rectosigmoid ulcerations on endoscopy. After unsuccessful trials of vedolizumab, infliximab, and tofacitinib, the patient was commenced on ustekinumab, tacrolimus, and oral vancomycin...
March 2024: ACG Case Reports Journal
https://read.qxmd.com/read/38469019/erythromelalgia-secondary-to-anti-tumor-necrosis-factor-tnf-alpha-therapy-a-report-of-two-cases
#39
Fatima Zahra El Rhaoussi, Zineb Boukhal, Fouad Haddad, Mohamed Tahiri, Wafaa Hliwa, Ahmed Bellabah, Badre Wafaa
Erythromelalgia is a rare syndrome with a generally unknown etiology. Whether primary or secondary, this condition is characterized by paroxysmal episodes of erythema, pain, and heat in the extremities. We report two cases of erythromelalgia occurring after the initiation of treatment with infliximab. The first case involves a 38-year-old patient who had been followed since August 2022 for ileocolonic Crohn's disease classified as A2L3B3 according to the Montreal classification, which was resistant to treatment and required infliximab therapy...
February 2024: Curēus
https://read.qxmd.com/read/38468819/a-teenage-girl-with-altered-mental-status-and-paraparesis
#40
Ryo Miyakawa, Janice Louie, Chris Keh, Lisa Chen, Babak Javid, Joel D Ernst, Neela Goswami, Felicia C Chow
A teenage girl presented with fever and altered mental status. MRI showed diffuse leptomeningeal enhancement of the brain and spine. She was diagnosed by a positive cerebrospinal fluid (CSF) culture with tuberculous (TB) meningitis and was started on anti-TB medications and corticosteroids. Her mental status improved, but she was noted to have proximal weakness of the lower extremities. In the course of tapering corticosteroids at week 11 of anti-TB therapy, she became acutely confused and febrile. MRI demonstrated interval development of tuberculomas in the brain and a mass lesion in the thoracic spine causing cord compression...
May 2024: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
keyword
keyword
1757
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.